Epilepsy miRNA Profile Depends on the Age of Onset in Humans and Rats

Jiri Baloun1, Petra Bencurova1,2, Tereza Totkova1, Hana Kubova3, Marketa Hermanova4, Michal Hendrych4, Martin Pail2, Sarka Pospisilova1 and Milan Brazdil1,2*

1 Central European Institute of Technology, Masaryk University, Brno, Czechia, 2 Brno Epilepsy Center, Department of Neurology, Medical Faculty of Masaryk University, St. Anne’s University Hospital, Brno, Czechia, 3 Department of Developmental Epileptology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia, 4 First Department of Pathology, Medical Faculty of Masaryk University, St. Anne’s University Hospital, Brno, Czechia

Temporal lobe epilepsy (TLE) is a severe neurological disorder accompanied by recurrent spontaneous seizures. Although the knowledge of TLE onset is still incomplete, TLE pathogenesis most likely involves the aberrant expression of microRNAs (miRNAs). miRNAs play an essential role in organism homeostasis and are widely studied in TLE as potential therapeutics and biomarkers. However, many discrepancies in discovered miRNAs occur among TLE studies due to model-specific miRNA expression, different onset ages of epilepsy among patients, or technology-related bias. We employed a massive parallel sequencing approach to analyze brain tissues from 16 adult mesial TLE (mTLE)/hippocampal sclerosis (HS) patients, 8 controls and 20 rats with TLE-like syndrome, and 20 controls using the same workflow and categorized these subjects based on the age of epilepsy onset. All categories were compared to discover overlapping miRNAs with an aberrant expression, which could be involved in TLE. Our cross-comparative analyses showed distinct miRNA profiles across the age of epilepsy onset and found that the miRNA profile in rats with adult-onset TLE shows the closest resemblance to the profile in mTLE/HS patients. Additionally, this analysis revealed overlapping miRNAs between patients and the rat model, which should participate in epileptogenesis and ictogenesis. Among the overlapping miRNAs stand out miR-142-5p and miR-142-3p, which regulate immunomodulatory agents with pro-convulsive effects and suppress neuronal growth. Our cross-comparison study enhanced the insight into the effect of the age of epilepsy onset on miRNA expression and deepened the knowledge of epileptogenesis. We employed the same methodological workflow in both patients and the rat model, thus improving the reliability and accuracy of our results.

Keywords: miRNA, mesial temporal lobe epilepsy, animal model, human, sequencing, cross-comparison study

INTRODUCTION

Temporal lobe epilepsy (TLE) is the most common type of epilepsy—a neurological disorder characterized by recurrent spontaneous seizures. This condition includes several subtypes, of which the most prevalent is mesial TLE (mTLE). The seizures of this subtype originate from the structures in the medial portion of the temporal lobe (such as the hippocampus) and are often associated with a pathological change of the hippocampal tissue—hippocampal sclerosis (HS)
The underlying mechanisms of epileptogenesis in TLE are still unclear; hence, a better understanding of involved biological processes is fundamental for novel treatment strategies and therapeutics. Among potential therapeutic targets as well as possible biomarkers of pathological changes in the epileptic brain are microRNAs (miRNAs).

miRNAs are small endogenous noncoding RNAs that act as posttranscriptional regulators of gene expression. Individual miRNAs can target a variety of miRNAs and most commonly inhibit their translation into proteins (Bartel, 2009). Hence, various mechanisms (e.g., methylation hormones and other miRNAs) strictly regulate miRNA expression (review in Gulyaeva and Kushlinskiy, 2016), because their dysregulation can have a profound effect on the cell, and, subsequently, on the whole organism. As a result, the monitoring of miRNA expression might disclose the onset or progression of the disease, making miRNAs a useful biomarker. This relation illustrates the close link between many diseases and altered levels of miRNAs (Srinivasan et al., 2013). The changes in miRNOME have been mostly studied in different types of cancer (Li and Kowdley, 2012), but the connection occurs in other conditions, including TLE. Numerous studies of miRNA dysregulation in TLE have provided solid evidence for their importance in the epilepsy pathogenesis (Brennan and Henschall, 2018).

To date, many studies about the role of miRNAs in epilepsy have produced a vast amount of data, however, they also have several drawbacks. Most of them studied epilepsy only in animal models, which have important limitations. Firstly, the animal model is only an approximation of mTLE, which does not correspond perfectly to the biochemistry of this disease in humans. Therefore, the results require cautious interpretation in the context of human mTLE. Moreover, there are fundamental differences between the animal models as each of them implements a different technique to induce epileptic seizures, making it difficult to compare the acquired data (Korotkov et al., 2017). Different experimental protocols can lead to the activation of different pathological pathways. Therefore, the processes involved in epileptogenesis can vary from one model to another. As a result, the affected miRNAs can also be unique to the experimental model and not represent epilepsy in general. Indeed, the results of these studies are often discordant (Korotkov et al., 2017).

Another fraction of the studies focuses on analyzing the miRNOME of human brain samples from epilepsy surgeries. This approach has the potential to provide results fully relevant to human mTLE, however, it is not flawless. Unlike TLE patients, controls were not treated with antiepileptic drugs (AEDs) affecting miRNA expression in the brain tissue. Furthermore, some complex factors can never be fully accounted for (such as lifestyle, age, gender, or ethnicity) (Leung and Sharp, 2010; Dluzen et al., 2016; Huan et al., 2018). These factors might affect the miRNA composition of the hippocampal tissue (Crespo et al., 2018) and cause inter-individual variability in both control and patient groups. Another discussed drawback is the origin of control brain tissues, which mostly come from postmortem autopsies, however, previous research discovered virtually unchanged miRNA composition in postmortem tissues within 30 h after death (Kakimoto et al., 2015; Bencurova et al., 2017).

The most promising approach is to compare the data acquired in animal models and human patients and find the intersection. Additionally, the same methodological workflow could enhance reliability and reduce the false negatives in the results. miRNAs identified by this approach are most likely related to epilepsy, rather than to a specific model or the origin of the tissue (surgery or autopsy). To date, only a few studies have used this approach (Roncon et al., 2015; Korotkov et al., 2017); therefore, we compared the miRNomes of patients with mTLE and a rat model of chronic epilepsy from our previous experiments (Bencurova et al., 2017). Moreover, the miRNA expression profile in the brain tissues changes during the development, and seizures might affect the direction of these changes. Our analyses also evaluated the effect of age at the first seizure occurrence on the miRNA profile in the chronic phase of this disease.

**MATERIALS AND METHODS**

**Human Samples**

All procedures involving human tissue processing were approved by the Ethical Committee of St. Anne's University Hospital in Brno (approval number 9G/2015-KS). The collection of the hippocampal tissue was performed on a cohort of anteromesial temporal resections at St. Anne's University Hospital in Brno, the Czech Republic, within the period 2007–2016. Patients and controls were previously described in Bencurova et al. (2017). In this study, we focused on a cohort of 16 adult mTLE/HS patients and 8 controls, hippocampal tissues of which were utilized for whole-miRNOME analysis by massive parallel sequencing (MPS). All patients (seven men and nine women) were referred to the Department of Neurology at the Brno Epilepsy Center for their medical intractability and fulfilled the diagnostic criteria for mTLE/HS. The diagnosis was made according to the International League Against Epilepsy (ILAE) criteria (Commission on Classification and Terminology of the ILAE, 1989). All of the patients had been routinely investigated, including long-term semi-invasive video-EEG monitoring (using sphenoidal electrodes), high-resolution magnetic resonance imaging (MRI), and neuropsychological testing. The diagnosis of unilateral mTLE in our patients was based on a consonance of history data, ictal and interictal EEG findings, ictal semiology, neuropsychology, and neuroimaging findings (MRI and PET). Unilateral HS concordant with the electroencephalographic lateralization of the epileptogenic zone was confirmed in all cases by visual inspections of the MRI scans by two independent physicians. None of the patients revealed other brain structural lesions on MRI scans or had undergone previous intracranial surgery. Age of TLE onset ranged from 2 to 44 years (mean = 16.9), and the average patient’s age at the time of surgery was 40.2 years (range = 25–51). All patients signed informed consent to approve the use of their tissue in this study. Control hippocampal tissue was collected from eight postmortem cases without hippocampal aberrations from the Department of Forensic Medicine at St. Anne’s University Hospital.

The average...
The Rat Model of TLE

Protocols involving animals were performed in accordance with ARRIVE guidelines (Kilkenny et al., 2010) and national (Act No 246/1992 Coll.) and international laws and policies (EU Directive 2010/63/EU for animal experiments). The Ethical Committee of the Czech Academy of Sciences approved the experimental protocols (Approval No. 128/2013). Status epilepticus (SE) was induced in male Wistar albino rats aged P12 (P—postnatal day) or P60 as described previously by Kubová et al. (2004). Briefly, all animals were labeled with a unique code and injected intraperitoneally (i.p.) with 127 mg/kg LiCl 24 h prior to pilocarpine/saline injection. Individual animals were tracked throughout the entire project based on the assigned code of each animal. Control and SE groups contained randomly assigned animals, and subjects in the SE group received a single i.p. dose of pilocarpine at P12 (35 mg/ml/kg) or P60 (45 mg/ml/kg); controls were treated with saline. All treated animals were caged separately and continually observed for 3 h. Latency to motor SE characterized by forelimb clonus was registered. Animals were treated with paraldehyde (P12: 0.07 ml/kg and P60: 0.3 ml/kg) approximately 2 h after the onset of convulsive SE in order to decrease mortality. Further experiments included only rats exhibiting behavioral manifestations of seizures progressing to forelimbs clonus for at least 1 h (SE was successfully induced in 100% of P12 and 69% of P60 animals injected with pilocarpine). Twelve P12 and 13 P60 animals were selected for experiments in the chronic stage of epilepsy (3 months after SE), along with 10 control animals per age group. For more details, see Supplementary Methods (submitted manuscript).

Monitoring

One week before being sacrificed, animals underwent continuous 24/7 video monitoring with IP infrared Camera Edimax IC-3140W for wireless monitoring. Synology Surveillance Station 7 software was used for both registration and evaluation. An experienced observer evaluated the recordings manually, registering the incidence of motor seizures (Racine stages 3–5). The electrographic analysis was omitted in order to prevent possible inflammatory reactions on EEG electrode implantation and the adverse effect of anesthesia exposure. The remainder of adult-onset animals (∼10) exhibited similar clonic seizures (frequency summarized in Supplementary Figure S1), while animals with SE at P12 and controls did not exhibit motor seizures (submitted manuscript).

Hippocampal Tissue Processing and RNA Isolation

Surgically resected and autopsy tissues from adult mTLE/HS patients and controls were identically treated: fixed in 10% neutral buffered formalin, grossly inspected, carefully oriented, and measured. Hippocampal tissue specimens were dissected into 2–3 mm-thick tissue slices along the anterior–posterior axis and paraffin embedded. Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with hematoxylin–eosin and evaluated under light microscopy; additionally, the presence of neuronal depletion and gliosis in HS tissue samples was confirmed using NeuN and GFAP immunohistochemistry. The international consensus classification of HS in TLE was applied (Blümcke et al., 2013). For miRNA analysis, paraffin-embedded tissue slices showing the presence of hippocampal complex were selected. Total RNA was isolated from tissue sections using the High Pure miRNA Isolation Kit (Roche) according to the manufacturer’s protocol. In order to maximize RNA yield, overnight Proteinase K digestion was used.

Hippocampal tissue was collected from 10 SE and 10 control animals per age group (n = 40) 3 months after SE (chronic stage of epilepsy). Animals were sacrificed by decapitation under the overdose of anesthesia (ether). Brains were immediately dissected, and the entire hippocampus was collected from both hemispheres. Tissues were immediately frozen in dry ice and stored at −80°C until further processing. Total RNA was isolated from frozen hippocampal tissue using the TRI Reagent® (Biotech) according to the manufacturer’s protocol. Ceramic beads were used for tissue disruption.

RNA was successfully extracted from all specimens and quantified using NanoDrop ND-1000 (Thermo Fisher Scientific) and QubitTM dsDNA HS Assay Kit on a Qubit® 2.0 fluorometer (Thermo Fisher Scientific). The 1.1 µg of extracted total RNA was used to prepare small RNA libraries and sequenced on NextSeq 500 (Illumina).

Massive Parallel Sequencing

Libraries for sequencing were prepared from 1.1 µg of total RNA obtained from rat samples (20 SE and 20 controls) and patients (16 mTLE and 8 controls). Libraries were prepared using a NEXTflex Small RNA-Seq Kit v2 for human samples and Kit v3 for rat samples (Bioo Scientific) according to the manufacturer’s protocol. After the amplification step, samples were analyzed using a Fragment Analyzer (Advanced Analytical), and specific fragments of the miRNA library (145 bp) were quantified. Samples were equally pooled for each particular sequencing run based on the concentration of miRNA library fragments, which were isolated using the Pippin Prep instrument using the 3% agarose (Sage Science) prior to sequencing. Isolated fragments were quantified using NanoDrop ND-1000 (Thermo Fisher Scientific) and Qubit® 2.0 fluorometer (Thermo Fisher Scientific) and used for sequencing on NextSeq 500 (Illumina) according to the manufacturer’s protocol.

MPS Data Processing and Differential Expression Analysis

Human sequencing data were processed as described previously (Bencurova et al., 2017). Adapter trimming, quality control, and miRNA annotation against miRBase v21 were performed using the Chimira (Vitsios and Enright, 2015) tool. Further
analyses were performed using R/Bioconductor packages (R Core Team, 2020).

MPS data from the rat TLE model were analyzed individually for each age group. Adaptor sequences were scanned and identified by the Kraken package (v15-065) (Davis et al., 2013) and removed with Cutadapt (v1.12) software (Martin, 2011). Only high-quality reads (Phred ≥ 10 over at least 85% of the read length) with a length between 16 and 28 bp after adapter trimming were retained as potential miRNA reads. The quality of both raw and processed reads was evaluated using FastQC software (Andrews, 1973). The raw miRNA expression levels were quantified by seqBuster (1.2.4a6) (maximum of one mismatch) with miRBase annotation (v22) (Kozomara and Griffiths-Jones, 2014).

Differential expression analysis was evaluated for both human and rat data by R package DESeq2 (Love et al., 2014). Raw data and annotated sequences of the small RNA libraries can be found in the GEO database (accession numbers GSE99455 and GSE124332).

The expression of miRNA was determined by microRNA quantitative PCR (miQPCR) as described by Benes et al. (2015). Primers were either designed manually or downloaded from the list of miQPCR primers, validated, and optimized for our samples according to the MIQE Guidelines (Bustin et al., 2009). The protocol used for amplification, quantification, and evaluation of miRNA expression using miQPCR was previously described in Bencurova et al. (2017).

**miRNA Target Prediction**

Target prediction tools were applied to address putative miRNA targets (miRDB - MicroRNA Target Prediction And Functional Study Database) (Wong and Wang, 2015) and pathways (DIANA-mirPath v3) affected by miRNAs with altered regulation in both mTLE/HS patients and the rat model of TLE. Only miRNAs showing the same trend of dysregulation (upregulated/downregulated) in both species were included in target and pathway prediction. Pathway prediction was based on predicted miRNA targets and experimentally validated miRNA interactions from DIANA-TarBase (Vlachos et al., 2015). Both MirTarget and DIANA-mirPath analyzed specific miRNA targets for species *Rattus norvegicus* and *Homo sapiens* individually.

**RESULTS**

**Whole miRNome Sequencing**

Our first high-throughput screening focused on profiling the miRNA expression in mTLE/HS patients and controls in order to identify aberrantly expressed miRNAs in this disease (Bencurova et al., 2017). Briefly, we sequenced the hippocampi of 16 patients and eight postmortem controls with median raw reads of 10.8 million per sample. The number of reads after adapter trimming and miRNA mapping dropped to 1.5 million per sample (12% of total) with high quality of sequencing represented by the PHRED-like score above 30 for 98.5% reads. The MPS analyses detected 401 miRNAs with the coverage over 500 reads in all samples together. The total sum of ambiguous base content was below 0.01% of all bases. Prior to the interpretation of differential expression analysis, we conducted additional analysis of gender-and age-related miRNAs in our dataset in order to prevent bias arising from uneven distribution of age and gender in patient and control groups. These analyses did not uncover any gender-specific miRNA with an altered expression level in mTLE/HS within our data, while miR-7110-3p upregulated (p = 0.028) in controls > 60 years of age was removed from follow-up analyses (data not shown). In our previous work, we described that miRNA distribution is impartial to the autopsy delay from the death of the subject and that the cellular composition of hippocampi is similar (based on the analysis of miRNAs enriched in specific cell types) in our patients and controls (Bencurova et al., 2017).

Parallel to human MPS, we sequenced rat hippocampi in the chronic stage of epileptogenesis (submitted manuscript). The final median of clean potential miRNA reads was 2.6 million (~53.91% of the raw reads) after adapter trimming, size selection of the trimmed reads, and removal of possible contaminants. Mapping to miRBase (v22) revealed the median content of miRNAs in the samples of 2.3 million (50.45% of the raw reads). Sequencing identified 412 unique miRNA species with read coverage > 500 across all the samples. The average PHRED-like quality score of all samples was above 35, which indicated very high sequencing quality. The total sum of ambiguous base content was < 0.01%. Since all rat individuals were age-matched males, housed under the same conditions, additional correlation analyses were unnecessary.

**miRNA Expression in TLE Patients and Model**

Principal component analysis (PCA) visualizes variation and uncovers distinct patterns in a dataset. This analysis showed different miRNA production between patients and rats – human individuals clustered separately from rats without any apparent effect of the age of TLE onset on the overall miRNA expression (Figure 1). Indeed, analysis of the differential expression using DESeq2 showed that only a fraction of over 400 identified miRNAs reached the threshold of differential expression (p < 0.05, fold change of upregulation or downregulation exceeding 1.4 and a minimum of 500 reads) in both human (Supplementary Table S2) and rat TLEs (Supplementary Table S3).

The basic concept suggests that the presence of seizures in childhood and adolescence could affect the miRNA expression profile and thus potentially introduce a defect in brain development (reviewed in Henshall, 2014; Rao and Pak, 2016). For this reason, we categorized and analyzed patient data in four categories based on their epilepsy onset age: (a) all patients together; (b) the first unprovoked seizure before the age of 10 (childhood); (c) between the 10th and 19th years (adolescent); and (d) at the age of 20 or later (adult onset).

The differential expression analysis of patients without respect to the first seizure was described in our previous study (Bencurova et al., 2017) and was focused on the detection of
dysregulated miRNAs in mTLE/HS patients whose age of the first unprovoked seizure was from 2 to 44 years. This group included mainly miRNAs previously associated with epilepsy, while nine of them have been described in epilepsy for the first time (Bencurova et al., 2017). Next, we searched in our MPS datasets for differentially expressed miRNAs in patients with the TLE onset between the ages of 2 and 9 years and discovered 123 miRNAs significantly dysregulated in patients. In the adolescence-onset category, 130 miRNAs were significantly dysregulated in TLE. The category with onset age above 20 contained 80 dysregulated miRNAs (Supplementary Table S2).

Of note, 49 miRNAs were significantly dysregulated in all age categories (Figure 2).

Since all patients underwent surgery in adulthood, the period between epilepsy onset and sample collection differed among childhood-onset (mean = 33.2 years, SD = 10.3), adolescent-onset (mean = 23 years, SD = 9.3), and adult-onset (mean = 11 years, SD = 11.9) categories. The duration of epilepsy might have affected the expression of detected miRNA, and correlations were found between the expression of miR-142-3p, miR-135a-5p, and miR-484 with the duration of epilepsy, but their effects were low, as displayed in Supplementary Figures S2, S4.

DESeq2 analysis of all rat samples combined identified 19 miRNAs differentially expressed in the post-SE rat (p < 0.05, minimal fold change of 1.4 with read count over 500 across all samples). When categorized by the onset age, 42 miRNAs showed altered expression in adult-onset and 12 in the infancy-onset model of TLE (Figure 2). However, only rno-miR-24-2-5p and miR-135a-5p were upregulated in both age groups (Supplementary Table S3; submitted manuscript).

To identify dysregulated miRNAs shared between patients and our animal model, we compared categorized rat miRNA profiles (infancy and adult onset) with data in each onset age category of patients. This comparison showed 19 miRNAs with significantly altered expression in both patients and TLE rats (Table 1), but seven of these miRNAs showed the opposite direction of regulation in rats compared with patients (Table 2). The overlap between human miRNA profile and the combined ages of onset categories in the rat was minimal. miR-142-3p showed common dysregulation across all patient categories and rat adult-onset group, and miR-135a-5p was dysregulated in rats (both age groups) and patients with epilepsy onset in adulthood (Table 1). miR-142-5p was dysregulated in patients with epilepsy onset in infancy, adolescence, and patients without categorization (all onset ages). Altogether, rats with SE in adulthood showed higher similarity with mTLE/HS patients in all categories, while the infancy-onset group corresponded with the human profile only in the case of miR-135a-5p and miR-140-5p (Figure 2).

In patient samples, miQPCR validated the dysregulation of miR-129-2-3p and miR-142-3p across all onset categories in patients, and let-7b-3p, miR-135-5p, and miR-140-5p increased in patients with TLE onset in adolescence (Table 1). Further, miQPCR confirmed increased expressions of miR-142-5p, miR-193-5p, and miR-203a-3p in one or more onset groups in patients along with the group without onset categorization. In the rat samples, miQPCR validated three out of 12 miRNAs, which overlapped with patients in their altered expression in TLE in our sequencing results: miR-142-5p, miR-484, and miR-539-5p in the adult-onset group.

Putative Targets of Dysregulated miRNAs

The MirTarget search tool (miRDB-MicroRNA Target Prediction And Functional Study Database) produced a list of putative mRNA targets of all identified miRNAs with shared dysregulation in SE animals and mTLE + HS patients. Table 3 shows brain-function-related targets with a target score of 90 or higher for humans and rats. Among the genes targeted in humans, the most frequent are potassium channels regulated by five miRNAs (miR-130b-3p, miR-135a-5p, miR-129-2-3p, miR-539-5p, and miR-484), followed by semaphorins and solute carriers of various molecules targeted by let-7b-3p and miR-135a-5p, miR-142-5p, and miR-539-5p. Solute carriers stand out also among mRNA
FIGURE 2 | Differentially expressed miRNA distribution across TLE onset stages. Venn diagrams showing the number of overlapping miRNAs with altered expression among (A) patients with different epilepsy onset ages; (B) both the rat model with different onset age and the rat model without onset age categorization; (C) patients without categorization and two rat models with different onset ages; (D) patients with epilepsy onset in infancy and both rat models of onset age; (E) patients with epilepsy onset in adolescence and both rat models of onset age; and (F) patients with epilepsy onset in adulthood and both rat models of onset age.

targets in rats with the same number of miRNAs involved in their regulation (let-7b-3p and miR-135a-5p, miR-142-5p, and miR-203a-3p). Unlike those in humans, calcium and sodium channels occur more frequently among targets than potassium channels, which are regulated only by miR-135a-5p in rats.

Similar to target prediction, humans had more affected pathways identified by DIANA-mirPath v3 software (Vlachos et al., 2015) compared with rat prediction data (Supplementary Table S5). In both cases, hundreds of genes undergo regulation by the combined force of miRNAs with shared dysregulation in mTLE patients and rats. Pathways common for both species predominantly comprised signaling pathways (Rap1, Ras, TGF-β, ubiquitin, etc.), however, circadian rhythm and gap junctions were also affected. In humans, this set of miRNAs also regulated the expression of genes involved in neurotransmitter synapses (dopaminergic, glutamatergic, and cholinergic) and axon guidance, while affecting the synaptic vesicle trafficking in rats.

DISCUSSION

The analysis of miRNA expression profile in brain tissues increasingly assists in the understanding of the biological processes involved in epileptogenesis and ictogenesis. However, previous comparative studies have explored the miRNA profiles mostly in patient samples affected by pharmacotherapies or models of epilepsy (e.g., cell culture AND animals), which do not correspond to the human biochemistry of the disease exactly.

This limitation can be overcome by miRNA profile comparison of patients and model organisms that may reveal specific miRNAs playing an essential role in the onset or development of mTLE. Here, we compared the miRNA profiles of patients and rat models of epilepsy analyzed with the same workflow. This approach reduced technological bias and enhanced the accuracy of discovered miRNAs.

In our analyses of MPS results, we focused on the effect of the onset age on the differential miRNA expression, which seems to be smaller in mTLE/HS patients since 49 miRNAs show altered expression in all onset categories (Figure 2). On the contrary, the onset age in the rat model strongly determines the changes in miRNA expression related to post-SE epilepsy, and the profiling study of the animal model revealed only a limited number of dysregulated miRNAs. This difference in miRNA expression between human and model might arise from multiple sources. For instance, tissue samples originated from patients long into their condition (the period from diagnosis to surgery ranges from 1 to 45 years), which means a long and variable progression of the disease (e.g., development of comorbidities or brain damage) and exposure to multiple AEDs. Exposure to AEDs might increase the variability between humans and rats since patients received levetiracetam and carbamazepine were commonly administered to patients across all age groups. Nevertheless, the inter-individual AED variability might have introduced inconsistency in patient miRNA levels unrelated to onset age (Supplementary Tables S1, S2). We also addressed a distinct subpopulation of mTLE patients, which shares similar features—drug resistance and HS. In the rat model,
### TABLE 1 | miRNA commonly dysregulated in mTLE/HS patients and TLE-like rats.

| miRNA       | Age category       | p-value MPS | Fold change MPS | p-value miQPCR | Fold change miQPCR |
|-------------|--------------------|-------------|-----------------|----------------|--------------------|
| (A) let-7b-3p | All onset ages     | 0.047       | 1.73            | 0.070          | 1.28               |
|             | 2–9 years (childhood) | 0.105    | 1.68            | 0.275          | 1.25               |
|             | 10–19 years (adolescence) | 0.027 | 2.53            | 0.042          | 1.46               |
|             | ≥ 20 years (adult)  | 0.266       | 2.32            | 0.794          | 1.06               |
| miR-129-2-3p | All onset ages     | 0.000       | 3.19            | 0.006          | 2.12               |
|             | 2–9 years (childhood) | 0.000    | 4.11            | 0.002          | 2.60               |
|             | 10–19 years (adolescence) | 0.000 | 4.12            | 0.008          | 2.18               |
|             | ≥ 20 years (adult)  | 0.000       | 3.10            | 0.034          | 2.34               |
| miR-130b-3p  | All onset ages     | 0.005       | −1.07           | 0.053          | 1.49               |
|             | 2–9 years (childhood) | 0.062    | −1.38           | 0.166          | 1.52               |
|             | 10–19 years (adolescence) | 0.063 | −1.33           | 0.076          | 1.62               |
|             | ≥ 20 years (adult)  | 0.000       | −1.45           | 0.566          | 1.24               |
| miR-135a-5p  | All onset ages     | 0.000       | 1.61            | 0.114          | 1.50               |
|             | 2–9 years (childhood) | 0.151    | 1.42            | 0.687          | 1.13               |
|             | 10–19 years (adolescence) | 0.099 | 1.54            | 0.046          | 1.73               |
|             | ≥ 20 years (adult)  | 0.026       | 1.75            | 0.209          | 1.69               |
| miR-140-5p   | All onset ages     | 0.105       | 1.05            | 0.180          | 1.27               |
|             | 2–9 years (childhood) | 0.012    | 1.38            | 0.665          | 1.10               |
|             | 10–19 years (adolescence) | 0.013 | 1.41            | 0.013          | 1.57               |
|             | ≥ 20 years (adult)  | 0.889       | −1.27           | 0.872          | 1.04               |
| miR-142-3p   | All onset ages     | 0.000       | 3.22            | 0.003          | 2.53               |
|             | 2–9 years (childhood) | 0.000    | 2.09            | 0.010          | 2.46               |
|             | 10–19 years (adolescence) | 0.000 | 2.42            | 0.010          | 2.46               |
|             | ≥ 20 years (adult)  | 0.000       | 2.19            | 0.035          | 2.14               |
| miR-142-5p   | All onset ages     | 0.000       | 2.66            | 0.004          | 2.34               |
|             | 2–9 years (childhood) | 0.001    | 2.10            | 0.010          | 2.68               |
|             | 10–19 years (adolescence) | 0.006 | 1.87            | 0.009          | 2.77               |
|             | ≥ 20 years (adult)  | 0.002       | 1.90            | –              | –                  |
| miR-193a-5p  | All onset ages     | 0.011       | 1.63            | 0.000          | 2.46               |
|             | 2–9 years (childhood) | 0.004    | 1.84            | 0.137          | 1.56               |
|             | 10–19 years (adolescence) | 0.010 | 1.83            | 0.036          | 2.21               |
|             | ≥ 20 years (adult)  | 0.098       | 1.59            | 0.456          | −1.21              |
| miR-203a-3p  | All onset ages     | 0.003       | 1.79            | 0.000          | 2.20               |
|             | ≥ 20 years (adult)  | 0.302       | 1.14            | 0.068          | 1.78               |
|             | 2–9 years (childhood) | 0.000    | 1.99            | 0.032          | 1.95               |
| miR-484     | All onset ages     | 0.013       | 1.05            | 0.025          | 2.54               |
|             | 2–9 years (childhood) | 0.004    | 1.34            | 0.151          | 2.79               |
|             | 10–19 years (adolescence) | 0.008 | 1.40            | 0.214          | 2.16               |
|             | ≥ 20 years (adult)  | 0.002       | 1.46            | 0.169          | 3.02               |
| miR-490-5p   | All onset ages     | 0.041       | 1.07            | 0.916          | 1.03               |
|             | 2–9 years (childhood) | 0.103    | 1.13            | 0.987          | 1.01               |
|             | 10–19 years (adolescence) | 0.021 | 1.38            | 0.450          | 1.28               |
|             | ≥ 20 years (adult)  | 0.002       | 1.44            | 0.290          | −1.39              |
| miR-539-5p   | All onset ages     | 0.025       | −1.53           | 0.182          | 2.25               |
|             | 2–9 years (childhood) | 0.001    | −1.73           | 0.378          | 2.64               |
|             | 10–19 years (adolescence) | 0.000 | −1.86           | 0.431          | 2.07               |
|             | ≥ 20 years (adult)  | 0.433       | −1.19           | 0.537          | 2.13               |

(Continued)
Table 1 | Continued

| miRNA          | Age category | MPS p-value | MPS Fold change | miQPCR p-value | miQPCR Fold change |
|----------------|--------------|-------------|----------------|---------------|-------------------|
| (B)            |              |             |                |               |                   |
| let-7b-3p      | All onset ages | 0.133       | 1.39           | 0.920         | −1.01            |
|                | P12 (infant)  | 0.948       | −1.01          | 0.811         | −1.05             |
|                | P60 (adult)   | 0.001       | 1.58           | 0.886         | 1.02             |
| miR-129-2-3p   | All onset ages | 0.025       | 1.23           | 0.102         | 1.13             |
|                | P12 (infant)  | 0.657       | 1.09           | 0.177         | 1.12             |
|                | P60 (adult)   | 0.005       | 1.66           | 0.182         | 1.15             |
| miR-130b-3p    | All onset ages | 0.001       | −2.07          | 0.770         | −1.05             |
|                | P12 (infant)  | 0.571       | −1.25          | 0.664         | 1.12             |
|                | P60 (adult)   | 0.002       | −3.48          | 0.120         | −1.24            |
| miR-135a-5p    | All onset ages | 0.000       | 1.50           | 0.093         | 1.23             |
|                | P12 (infant)  | 0.007       | 1.46           | 0.211         | 1.49             |
|                | P60 (adult)   | 0.001       | 1.58           | 0.314         | 1.16             |
| miR-140-5p     | All onset ages | 0.014       | 1.40           | 0.722         | −1.02            |
|                | P12 (infant)  | 0.018       | 1.42           | 0.224         | 1.11             |
|                | P60 (adult)   | 0.099       | 1.27           | 0.100         | −1.17            |
| miR-142-3p     | All onset ages | 0.040       | 1.23           | 0.716         | −1.03            |
|                | P12 (infant)  | 0.312       | 1.24           | 0.742         | 1.04             |
|                | P60 (adult)   | 0.040       | 1.54           | 0.332         | −1.09            |
| miR-142-5p     | All onset ages | 0.075       | 1.36           | −          | −               |
|                | P12 (infant)  | 0.989       | −1.00          | 0.109         | 1.56             |
|                | P60 (adult)   | 0.012       | 1.58           | 0.010         | 2.61             |
| miR-193a-5p    | All onset ages | 0.008       | 1.24           | 0.753         | −1.07            |
|                | P12 (infant)  | 0.152       | 1.33           | 0.000         | −1.65            |
|                | P60 (adult)   | 0.026       | 1.58           | 0.145         | 1.45             |
| miR-203a-3p    | All onset ages | 0.018       | 1.24           | 0.904         | 1.01             |
|                | P12 (infant)  | 0.711       | −1.05          | 0.630         | −1.09            |
|                | P60 (adult)   | 0.000       | 1.57           | 0.368         | 1.11             |
| miR-484        | All onset ages | 0.057       | 1.51           | 0.121         | 1.23             |
|                | P12 (infant)  | 0.754       | 1.08           | 0.579         | 1.51             |
|                | P60 (adult)   | 0.009       | 1.87           | 0.023         | 1.53             |
| miR-490-5p     | All onset ages | 0.460       | 1.09           | 0.113         | −1.23            |
|                | P12 (infant)  | 0.471       | −1.27          | 0.001         | −1.58            |
|                | P60 (adult)   | 0.039       | 1.99           | 0.733         | 1.04             |
| miR-539-5p     | All onset ages | 0.081       | −1.09          | 0.017         | −1.22            |
|                | P12 (infant)  | 0.960       | 1.01           | 0.563         | −1.06            |
|                | P60 (adult)   | 0.028       | −1.43          | 0.000         | −1.41            |

List of miRNAs with altered expression determined by MPS and their miQPCR validation in (A) mTLE/HS patients and (B) rats 3 months after SE. miRNAs are displayed for each analyzed onset age category and all samples per species together (altogether 12 unique miRNAs). p-values below 0.05 are in bold. Fold changes < −1.4 or > 1.4 are in bold. Empty cells indicate impossibility to analyze miRNA expression due to high Ct values (>32) in miQPCR.

Potential bias increasing the influence is suppressed, and hence, the P12 and P60 groups differed solely in the age of SE induction and its consequences. We used age- and gender-matched controls for each age group; animals were not exposed to any medications besides those necessary for the model development, and they lived in a controlled environment. Furthermore, the outcome of SE induction at P12 in rats typically results in a slightly different condition than the model of SE in adult animals. Unlike adults, animals with SE at P12 develop only electrographic seizures during the chronic stage of the disease (motor seizures are not present), and they show a more discrete level of brain damage even though similar structures are affected (Nairismägi et al., 2006; Kubová and Mareš, 2013). On the other hand, induction of SE during brain development results in early manifestations of comorbidities such as impaired learning and memory problems (Rutten et al., 2002; Kubová et al., 2004; Mikulecká et al., 2019). These differences arising from the onset age in our model might explain the difference in miRNA profiles between rats with infant- and adult-onset TLEs.
TABLE 2 | miRNA with opposite dysregulation in mTLE/HS patients and TLE-like rats.

| First seizure | Human mTLE + HS | Rat 3 months after SE |
|---------------|----------------|-----------------------|
| All onset ages | miR-22-3p ** | miR-187-3p ** |
| miR-203a-3p ** | miR-211-5p ** |
| 2–9 years (childhood) | miR-301a-3p ** | miR-301a-3p ** |
| miR-22-3p ** | miR-376a-3p * |
| miR-301a-3p ** | miR-92b-5p * |
| 10–19 years (adolescence) | miR-187-3p * | miR-22-3p * |
| miR-211-5p * | miR-301a-3p * |
| miR-212-3p * | miR-376a-3p * |
| miR-22-3p * | miR-187-3p * |
| miR-301a-3p * | miR-212-3p ** |
| ≥20 years (adult) | miR-301a-3p ** | miR-22-3p ** |
| miR-211-5p ** | miR-301a-3p ** |
| miR-376a-3p ** | miR-301a-3p ** |
| miR-92b-5p | miR-301a-3p ** |

List of miRNAs with altered expression (**p-value < 0.01; *p-value < 0.05; fold change over 1.4) with an opposite trend of dysregulation in mTLE/HS patients and rats 3 months after SE screened by MPS. miRNAs are displayed for each analyzed onset age category and all samples per species together (altogether seven unique miRNAs). FC—differential expression fold change.

10 were also dysregulated in rats with onset in adulthood. In contrast, only miR-140-5p and miR-135a-5p showed concordant dysregulation in rats with onset in infancy (Table 1 and Figure 2). Though the overlap with early-onset TLE in rats is minimal in our data, miR-140-5p shows elevated expression specific for this age group of rats and patients with adolescent-onset mTLE, which would be neglected if compared solely to the adult-onset model. The other reason for the limited overlap of miRNA profiles between the human and early-onset model of TLE might lie in the age difference – even though categorized, human patients underwent surgery with a large delay from the beginning of the disease after extensive medication. Moreover, the resemblance of human and rat with adult-onset miRNA profiles might be partially due to the presence of severe brain damage in these rats, indicating better resemblance of this model to patients with HS in mTLE/HS (Turski et al., 1986). Taken together, although our study showed cardinal differences between human and rat miRNA profiles in hippocampi, the results indicate that miRNA expression changes in mTLE/HS patients are more similar to rats with onset in adulthood than rats with onset in the infancy.

Nevertheless, almost all miRNAs detected by MPS and listed in Table 1 were previously associated with epilepsy showing the same trend of dysregulation either in both patients and animal models (miR-129-2-3p, miR-135-5p and miR-193a-5p) or in just animal models of epilepsy (miR-140-5p, miR-142-3p, miR-142-5p, miR-203a-3p, and miR-539) (Kan et al., 2012; Risbud and Porter, 2013; Gorter et al., 2014; Kretschmann et al., 2014). In the case of miR-130b-3p, dubious results were previously reported showing both upregulation and downregulation of this miRNA in both patient and animal models of TLE (Liu et al., 2010; McKiernan et al., 2012a,b; Kaalund et al., 2014). let-7b-3p was reported by Risbud and colleagues as downregulated in rats with pilocarpine-induced SE, while miR-484 and miR-490-5p have not been associated with epilepsy so far (Supplementary Table S6). Additionally, we found an opposite significant dysregulation of seven miRNAs between patients and rats (Table 2). We did not study the reason for these opposite expressions and can only speculate that they arise from a specific reaction of the rat model on TLE onset or the specificity of this animal epilepsy model. The majority of these contradicting miRNAs were previously associated with epilepsy only in animal models. Kan et al. (2012) observed (2012), similarly to our data, the elevation of miR-301a-3p in their study of mTLE patients. On the other hand, miR-187-3p and miR-211-5p were previously identified as downregulated in human patients, which corresponds with the trend of dysregulation we observed in the rat model rather than in patients (McKiernan et al., 2012a; Kaalund et al., 2014).

This cross-comparison study of our previous miRNA profiling analyses showed that the expression of miR-142-5p was significantly dysregulated in the MPS results of patients (in all age groups) and rats with seizure onset in adulthood, but it was validated only in the patient group. To identify the potential targets of this miRNA, we employed miRDB software, which predicts about 300 potential mRNA targets involved in various pathways (e.g., signaling and cell cycle). Literature indicates that these mRNA target genes were included in immunomodulatory pathways. These studies showed in a functional experiment that miR-142-5p negatively regulates the expression of pro-inflammatory agents, interleukin 6 (IL-6), or high mobility group box (HMGB) gene, which are considered pro-convulsive (Kretschmann et al., 2014; Britton, 2016). This evidence supports the idea that autoimmunity plays a significant role in ictogenesis and epileptogenesis and shall be considered in epilepsy management. Besides, ILAE has recognized autoimmune epilepsy as a distinct entity and included it into classification since 2017 (Britton, 2016).

Another miRNA with great influence on TLE might be miR-135a-5p, which was significantly altered in patients and both rat models of mTLE. However, we did not validate this miRNA by miQPCR due to its low amount in samples. Based on the literature, this miRNA mediates the expression of various...
### TABLE 3 | Predicted targets of miRNA commonly dysregulated in human and rat TLEs.

| miRNA | Gene Product | Human | Gene Product | Rat |
|-------|--------------|-------|--------------|-----|
| let-7b-3p | BDNF | Brain-derived neurotrophic factor | BDNF | Brain-derived neurotrophic factor |
| | CACNA1C | Calcium voltage-gated channel subunit alpha 1 C | GLS | Glutaminase |
| | CAMTA1 | Calmodulin binding transcription activator 1 | NPY1R | Neuropeptide Y receptor Y1 |
| | CARF | Calcium responsive transcription factor | SCN7a | Sodium voltage-gated channel alpha subunit 7 |
| | CEPT1 | Choline/ethanolamine phosphotransferase 1 | SLC18A2 | Solute carrier family 18 member A2 (monoamines) |
| | GABRG1 | Gamma-aminobutyric acid type A receptor gamma 1 subunit | SYNAP3 | Synaptogyrin 3 (synaptic vesicles) |
| | GLS | Glutaminase | | |
| | GPR37 | G protein-coupled receptor 37 | | |
| | GRM5 | Glutamate metabotropic receptor 5 | | |
| | MNX1 | Motor neuron and pancreas homeobox 1 | | |
| | NBEA | Neurobeachin (neuron specific post-Golgi membrane traffic) | | |
| | NEUROG2 | Neurogenin 2 (differentiation and survival of dopaminergic neurons) | | |
| | NQO1 | Neurogudin (development of nervous system) | | |
| | NLRN1 | Neurilgin 1 (formation and remodeling of synapses) | | |
| | NPY | Neuropeptide Y | | |
| | NRP2 | Neuregulin 2 (axon guidance) | | |
| | PSD2 | Pleckstrin and Sec7 domain containing 2 (endocytosis) | | |
| | SCAMP1 | Secretory carrier membrane protein 1 | | |
| | SEMA3C | Semaphorin 3C | | |
| | SLC18A2 | Solute carrier family 18 member A2 (monoamines) | | |
| | SLC6A17 | Solute carrier family 6 member 17 (presynaptic uptake of most neurotransmitters) | | |
| | SLC6A4 | Solute carrier family 6 member 4 (serotonin) | | |
| | SNCAIP | Synuclein alpha interacting protein | | |
| | SYNAP3 | Synaptogyrin 3 (synaptic vesicles) | | |
| | TVP23B, C | Trans-Golgi network vesicle protein 23 homolog B and C | | |
| | VAPA | VAMP-associated protein A | | |
| miR-129-2-3p | GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| | KCNB1 | Potassium voltage-gated channel subfamily B member 1 | SCN3B | Sodium channel, voltage-gated, type III, beta |
| | MPZL1 | Myelin protein zero like 1 | | |
| | NPTN | Neuroplastin (synaptic membrane Ig) | | |
| | SAC5 | Saccin molecular chaperone | | |
| | SCN3B | Sodium voltage-gated channel beta subunit 3 | | |
| miR-130b-3p | CLCN3 | Chloride voltage-gated channel 3 | CLCN3 | Chloride voltage-gated channel 3 |
| | CLTC | Clathrin heavy chain | NEUROG1 | Neurogenin 1 |
| | GJA1 | Gap junction protein alpha 1 | | |
| | KCNA4 | Potassium voltage-gated channel subfamily A member 4 | | |
| | NEUROG1 | Neurogenin 1 | | |
| | RTN1 | Reticulin 1 (neuroendocrine secretion) | | |
| | STON2 | Storin 2 (clathrin-associated) | | |
| | SYBU | Syntabulin (axonal transport) | | |
| miR-135a-5p | CACNA1D | Calcium voltage-gated channel subunit alpha 1 D | CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit |
| | CACNA1E | Calcium voltage-gated channel subunit alpha 1 E | CPLX1 | Complexin 1 (binding SNARE, synaptic transport) |
| | CPLX1 | Complexin 1 (synaptic vesicles) | KCNAB3 | Potassium voltage-gated channel subfamily A regulatory beta subunit 3 |
| | CPLX2 | Complexin 2 (synaptic vesicles) | KCND1 | Potassium voltage-gated channel subfamily D member 1 |
| | GRIA3 | Glutamate ionotropic receptor AMPA type subunit 3 | KCNJ6 | Potassium voltage-gated channel subfamily J member 6 |
| | GRID2 | Glutamate ionotropic receptor delta type subunit 2 | KCNS3 | Potassium voltage-gated channel, modifier subfamily S, member 3 |

(Continued)
### TABLE 3 | Continued

| miRNA     | Human                     | Rat                      |
|-----------|---------------------------|--------------------------|
|           | Gene                      | Product                  | Gene                      | Product                              |
|           |   |                          |                          | NTNG1       | Netrin G1 (axon guidance)            |
| miR-140-5p|                      |                          |                          | SL2C4A2     | Solute carrier family 24 member 2 (calcium/cation antiporter) |
|           |                      |                          |                          | SL5C5A1     | Solute carrier family 5 (sodium/choline cotransporter), member 7 |
| miR-142-3p| CLDN12                   | Claudin 12 (tight junctions) |                          |             |                          |
|           | CLOCK                    | Clock circadian regulator|                          |             |                          |
|           | CLTA                     | Caltxin light chain A    |                          |             |                          |
| miR-142-5p| CBLN4                    | Cerebellin 4 precursor (synapse development) | NEDD1       | Neural precursor cell expressed, developmentally downregulated 1 |
|           | CNTN1                    | Contactin 1 (neuronal adhesion) | SEPT2       | Septin 2 (axon growth)               |
|           | NENF                     | Neurexin neurotrophic factor | SLC12A1     | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 |
|           | SACs                     | Sarcin molecular chaperone | SLC01B2     | Solute carrier organic anion transporter family, member 1B2 |
|           | SLC24A2                  | Solute carrier family 24 member 2 (calcium/cation antiporter) |                  |                                      |
|           | SLC24A2                  | Solute carrier family 24 member 2 (calcium/cation antiporter) |                  |                                      |
|           | SLC9A9                   | Solute carrier family 9 member A9 (sodium/proton exchanger) |                  |                                      |
|           | SV2B                     | Synaptic vesicle glycoprotein 2B |                  |                                      |
|           | SYT2                     | Synaptotagmin 2           |                  |                                      |
|           | SYT3                     | Synaptotagmin 3           |                  |                                      |
| miR-193a-5p| CLCA2                   | Chloride channel accessory 2 | CACNB4       | Calcium voltage-gated channel auxiliary subunit beta 4 |
|           | NETO2                    | Neuruplin and fodrin like 2 (axon guidance) |                  |                                      |
| miR-203a-3p| CAB39                   | Calcium binding protein 39| CACNA2D1     | Calcium voltage-gated channel auxiliary subunit alpha 2 delta 1 |
|           | CNTN1                   | Contactin 1 (neuronal adhesion) |                  |                                      |
|           | MYEF2                   | Myelin expression factor 2| GABARP1       | GABA type A receptor associated protein like 1 |
|           | NOCT                    | Nocturnal (circadian rhythm) | GABRA1       | Gamma-aminobutyric acid type A receptor alpha 1 subunit |
|           | OLFM3                   | Olfactomedin 3           | SCN2A        | Sodium voltage-gated channel alpha subunit 2 |
|           | PSD3                    | Pleckstrin and Sec7 domain containing 3 (endocytosis) | SEMA5A       | Semaphorin 5A (axon guidance) |
|           | SEMA5A                  | Semaphorin 5A (axon guidance) | SLC12A2     | Solute carrier family 12 member 2 (Na/K/2Cl cotransporter) |
|           | SGMS2                   | Sphingomyelin synthase 2 | SLC9A5       | Solute carrier family 9 member A5 (Na⁺/H⁺) |
| miR-484   | KCNJ14                  | Potassium voltage-gated channel subfamily J member 14 |                  |                                      |
| miR-490-5p| TNFR                    | Tenascin R (axon growth)  |                  |                                      |
| miR-539-5p| GABRA4                  | Gamma-aminobutyric acid type A receptor alpha 4 subunit | NELL2        | Neural EGFL like 2 |
|           | KCNB1                   | Potassium voltage-gated channel subfamily B member 1 | SEMA3D       | Semaphorin 3D (axon guidance) |
|           | KCNG3                   | Potassium voltage-gated channel modifier subfamily G member 3 |                  |                                      |
|           | NAV1                    | Neuron Navigator 1       |                  |                                      |
|           | NELL2                   | Neural EGFL like 2       |                  |                                      |

(Continued)
proteins included in brain function and neuron development, e.g., serotonin receptor and transporter (Artigas et al., 2018) or complexin 1/2 in the amygdala (Mannironi et al., 2018). It also regulates developmental axon growth and branching, cortical neuronal migration, or regeneration of retinal ganglion cell axons (van Battum et al., 2018). Besides, recent findings revealed that miR-135a-5p affects spontaneous recurrent seizures in the TLE model (Vangoor et al., 2019), which confirms our finding.

Besides, miR-142-5p, miR-142-3p, and miR-129-2-3p have also altered expressions across all patient categories and adult-onset TLE in rats. Functional studies showed that miR-142-3p affects not only immunomodulation via control of IL-1β and IL-10 but also the expression of D1 dopaminergic receptors while suppressing neuronal growth (Tobón et al., 2012; Mandolesi et al., 2017). In the case of miR-129-2-3p, our target prediction indicated regulation of γ-aminobutyric acid receptor 1 (GABRA1) and sodium voltage-gated channel common for both humans and rats (Table 2). Previous experiments on cell cultures suggest that miR-129-2-3p represses expression of caspase 6 and spleen tyrosine kinase (SYK) (Huang et al., 2019; Umehara et al., 2019).

Among limitations of this study belongs the age discrepancy between the epilepsy onset and the resection of epileptic foci in patients, which is different from the condition in the rat model of epilepsy. Another potential drawback is patient classification based only on the age onset since different classifications (e.g., etiology based) might yield different results. Due to the small amount of unique patient samples and limited sensitivity of miQPCR, we did not validate discovered miRNAs. Finally, predicted gene targets of discussed miRNAs were generated in silico, and they require validation in brain tissues by functional experiments.

In summary, our cross-comparison study compared miRNA profiles of mTLE/HS patients with two different age-onset rat models of TLE. This comparison was focused on both miRNA profiles of all patients and patients categorized based on epilepsy onset age, which plays a substantial role in disorder outcome. These analyses confirmed particular dysregulation of miRNA expression in different onset ages and discovered several miRNAs, which might be truly connected to epileptogenesis and ictogenesis in both patients and animal models. Our analyses also showed that rats with TLE onset in adulthood showed greater resemblance to miRNA profiles of mTLE/HS patients than rats with onset in infancy. Finally, our study enhanced insight into the general knowledge of epilepsy and should be considered in the planning of future epilepsy experiments with animal models.

### DATA AVAILABILITY STATEMENT

The datasets generated for this study can be found in the GEO database (accession numbers GSE99455 and GSE124332).

### ETHICS STATEMENT

Written informed consent was obtained from the individual(s) and/or minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article. The studies involving human participants were reviewed and approved by the Ethical Committee of St. Anne’s University Hospital in Brno (approval number 9G/2015-KS). The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Ethical Committee of the Czech Academy of Sciences (approval number 128/2013).

### AUTHOR CONTRIBUTIONS

This manuscript has been read and approved by all named authors and all authors agreed with the order of authors listed in the manuscript. The authors consent to take public responsibility for the content of the manuscript and confirm that the manuscript was prepared following ethical guidelines and regulations of their institutions concerning intellectual property. All authors have had access to all the data in the study and contributed to the study design, data acquisition, data analysis, interpretation, drafting, and revising the manuscript.

### FUNDING

This work has received funding from the Czech Science Foundation (Project Nos. GA16-04726S and 19-11931S); the
Ministry of Education, Youth and Sports of the Czech Republic under the National Sustainability Program II project CEITEC 2020 (LQ1601), the support for long-term conceptual development of research organization RVO: 67985823.

ACKNOWLEDGMENTS

We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2020.00924/full#supplementary-material

REFERENCES

Andrews, S. (1973). Babraham bioinformatics - FastQC a quality control tool for high throughput sequence data. Soil 5, 47–81. doi: 10.1016/0038-0717(73)90903-X

Artigas, F., Celaeda, P., and Bortolozzi, A. (2018). Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies. Eur. Neuropsychopharmacol. 28, 457–482. doi: 10.1016/j.euroneuro.2018.01.005

Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233. doi: 10.1016/j.cell.2009.01.002

Bencurova, P., Baloun, J., Musilova, K., Radova, L., Tichy, B., Pail, M., et al. (2017). MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: whole miRNome profiling of human hippocampus. Epilepsia 58, 1782–1793. doi: 10.1111/epp1.13870

Benes, V., Collier, P., Kordes, C., Stolte, J., Rausch, T., Muckenthaler, M. U., et al. (2014). MicroRNAs and epilepsy: profiling, functions and potential clinical applications. Curr. Opin. Neuro. 27, 199–205. doi: 10.1016/7/WCO.000000000000079

Huan, T., Chen, G., Liu, C., Bhattacharya, A., Kong, J., Chen, B. H., et al. (2018). Age-associated microRNA expression in human peripheral blood is associated with all-cause mortality and age-related traits. Aging Cell 17:e12687. doi: 10.1111/acel.12687

Huang, S., Lv, Z., Wen, Y., Wei, Y., Zhou, L., Ke, Y., et al. (2019). miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population. J. Cell. Mol. Med. 23, 167–176. doi: 10.1111/jcmm.13901

Kaalund, S. S., Veno, M. T., Bak, M., Møller, R. S., Laursen, H., Madsen, F., et al. (2014). Aberrant expression of mir-218 and miR-204 in human mesial temporal lobe epilepsy and hippocampal sclerosis-Convergence on axonal guidance. Epilepsia 55, 2017–2027. doi: 10.1111/epp1.12839

Kakimoto, Y., Kamiguchi, H., Ochiai, E., Satoh, F., and Osaawa, M. (2015). MicroRNA stability in postmortem FFPE tissues: quantitative analysis using autotopic samples from acute myocardial infarction patients. PLoS One 10:e0129338. doi: 10.1371/journal.pone.0129338

Kan, A. A., van Erp, S., Derijck, A. A. H. A., de Wit, M., Hessel, E. V. S., D’Oubhier, E., et al. (2012). Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell. Mol. Life Sci. 69, 3127–3145. doi: 10.1007/s00018-012-092-99-27

Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., and Altman, D. G. (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e1000412. doi: 10.1371/journal.pbio.1000412

Korotkov, A., Mills, J. D., Gorter, J. A., Van Vliet, E. A., and Aronica, E. (2017). Systematic review and meta-analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy. Sci. Rep. 7:11592. doi: 10.1038/s41598-017-11510-8

Kozomara, A., and Griffiths-Jones, S. (2014). MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73. doi: 10.1093/nar/gkt1181

Kretschmann, A., Danis, B., Andonovic, L., Abnaf, K., van Rikxoort, M., Siegel, F., et al. (2014). Different microRNA profiles in chronic epilepsy versus acute seizure mouse models. J. Mol. Neurosci. 55, 466–479. doi: 10.1007/s12031-014-0368-6

Kubová, H., and Mareš, P. (2013). Are morphologic and functional consequences of status epilepticus in infant rats progressive? Neuroscience 235, 232–249. doi: 10.1016/j.neuroscience.2012.12.055

Kubová, H., Mares, P., Suchomelová, L., Brozek, G., Druga, R., and Pitkänen, A. (2004). Status epilepticus in immature rats leads to behavioural and cognitive impairment and epileptogenesis. Eur. J. Neurosci. 19, 3255–3265. doi: 10.1111/j.0953-816X.2004.03410.x

Leung, A. K. L., and Sharp, P. A. (2010). MicroRNA functions in stress responses. Mol. Cell. 40, 205–215. doi: 10.1016/j.molcel.2010.09.027

Li, Y., and Kowdley, K. V. (2012). MicroRNAs in common human diseases. Genomics Proteomics Bioinforma. 10, 246–253. doi: 10.1016/j.gpb.2012.07.005

Liu, D. Z., Tian, Y., Ander, B. P., Xu, H., Stamosa, B. S., Zhan, X., et al. (2010). Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J. Cereb. Blood Flow Metab. 30, 92–101. doi: 10.1038/jcbfm.2009.186

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with Deseq2. Genome Biol. 15:550. doi: 10.1186/s13059-014-0550-8
Mandolesi, G., De Vito, F., Musella, A., Gentile, A., Bullitta, S., Fresigna, D., et al. (2017). MiR-142-3p is a key regulator of IL-1β-dependent synaptopathy in neuroinflammation. J. Neurosci. 37, 546–561. doi: 10.1523/JNEUROSCI.0851-16.2016

Mannironi, C., Biundo, A., Rajendran, S., De Vito, F., Saba, L., Caioli, S., et al. (2018). miR-135a regulates synaptic transmission and anxiety-like behavior in amygdala. Mol. Neurobiol. 55, 3301–3315. doi: 10.1007/s12035-017-0564-9

Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10–12. doi: 10.14806/ej.17.1.200

McKernan, R. C., Jimenez–Mateos, E. M., Bray, I., Engel, T., Brennan, G. P., Sano, T., et al. (2012a). Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One 7:e35921. doi: 10.1371/journal.pone.0035921

McKernan, R. C., Jimenez-Mateos, E. M., Sano, T., Bray, I., Stallings, R. L., Simon, R. P., et al. (2012b). Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death. Exp. Neurol. 237, 346–354. doi: 10.1016/j.expneuro.2012.06.029

Mikulecká, A., Druga, R., Stuchlík, A., Mareš, P., and Kubová, H. (2019). Comorbidities of early-onset temporal epilepsy: cognitive, social, emotional, and morphologic dimensions. Exp. Neurol. 320, 113005. doi: 10.1016/j.expneuro.2019.113005

Nairismägi, J., Piktänen, A., Ketunen, M. I., Kauppinen, R. A., and Kubová, H. (2006). Status epilepticus in 12-day-old rats leads to temporal lobe neurodegeneration and volume reduction: a histologic and MRI study. Epilepsia 47, 479–488. doi: 10.1111/j.1528-1167.2006.00455.x

Rao, Y. S., and Pák, T. R. (2016). microRNAs and the adolescent brain: filling the knowledge gap. Neurosci. Biobehav. Rev. 70, 313–322. doi: 10.1016/j.neubiorev.2016.06.008

Risbud, R. M., and Porter, B. E. (2013). Changes in MicroRNA Expression in the whole hippocampus and hippocampal synaptoneurosome fraction following pilocarpine induced status epilepticus. PLoS One 8:e53464. doi: 10.1371/journal.pone.0053464

Roncon, P., Soukupová, M., Binaschi, A., Falcicchia, C., Zucchini, S., Ferracin, M., et al. (2015). MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy – comparison with human epileptic samples. Sci. Rep. 5:14143. doi: 10.1038/srep14143

Rutten, A., Van Albada, M., Silveira, D. C., Cha, B. H., Liu, X., Hu, Y. N., et al. (2002). Memory impairment following status epilepticus in immature rats: time-course and environmental effects. Eur. J. Neurosci., 16, 501–513. doi: 10.1046/j.1460-9586.2002.02103.x

Srinivasan, S., Selvan, S. T., Archunan, G., Gulyas, B., and Padmanabhan, P. (2013). MicroRNAs—the next generation therapeutic targets in human diseases. Theranostics 3, 930–942. doi: 10.7150/thno.7026

Thom, M., Eriksson, S., Martinian, L., Caboclo, L. O., McEvoy, A. W., Duncan, J. S., et al. (2009). Temporal lobe sclerosis associated with hippocampal sclerosis in temporal lobe epilepsy: neuropathological features. J. Neuropathol. Exp. Neurol. 68, 928–938. doi: 10.1097/NEN.0b013e3181b05d67

Tobin, K. E., Chang, D., and KuzhiKandathil, E. V. (2012). MicroRNA 142-3p mediates post-transcriptional regulation of D1 dopamine receptor expression. PLoS One 7:e49288. doi: 10.1371/journal.pone.0049288

Turski, L., Cavaleirho, E. A., Sieklucka-Dziuba, M., Iononimouidou-Turski, C., Czuczwar, S. J., and Turski, W. A. (1986). Seizures produced by pilocarpine: neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain. Brain Res. 398, 37–48. doi: 10.1016/0006-8993(86)91247-3

Umehara, T., Mori, R., Mace, K. A., Murase, T., Abe, Y., Yamamoto, T., et al. (2019). Identification of specific miRNAs in neutrophils of type 2 diabetic mice: overexpression of miRNA-129-2-3p accelerates diabetic wound healing. Diabetes 68, 617–630. doi: 10.2337/db18-0313

van Batten, E. Y., Verhagen, M. G., Vangoor, V. R., Fuita, Y., Derijck, A. H. A., O’Duibhir, E., et al. (2018). An image-based microRNA screen identifies miRNA-135s as regulators of CNS axon growth and regeneration by targeting kruüpel-like factor 4. J. Neurosci. 38, 613–630. doi: 10.1523/JNEUROSCI.0662-17.2017

Vangoor, V. R., Reschke, C. R., Senthilkumar, K., Van De Haar, L. L., de Wit, M., Giuliani, G., et al. (2019). Antagonizing increased miR-135a levels at the chronic stage of experimental TLE reduces spontaneous recurrent seizures. J. Neurosci. 39, 5064–5079. doi: 10.1523/JNEUROSCI.3014-18.2019

Vitos, D. M., and Enright, A. J. (2015). Chimira: analysis of small RNA sequencing data and microRNA modifications: fig. 1. Bioinformatics 31, 3365–3367. doi: 10.1093/bioinformatics/btv380

Vlachos, I. S., Zagganas, K., Paraskevopoulou, M. D., Georgakilas, G., Karagkouni, D., Vergoulis, T., et al. (2015). DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43, W460–W466. doi: 10.1093/nar/gku403

Wong, N., and Wang, X. (2015). miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43, D146–D152. doi: 10.1093/nar/gku1104

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Baloun, Benčurová, Totkova, Kubová, Hermanova, Hendrych, Pail, Pospisilova and Brazdil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.